Skip to main content

Table 2 Details of 1512 women who received MgSO4 for fetal NP administration and adverse effects during MAG-CP (N (%) women unless otherwise specified)

From: MAGnesium sulphate for fetal neuroprotection to prevent Cerebral Palsy (MAG-CP)—implementation of a national guideline in Canada

  N (%) or median [IQR]
Gestational age at time of MgSO4 therapy (week) 27.1 [25.6, 28.4]
Cervical dilatation at time of therapy (cm) 3 [1.5,4.5]
 Cervical dilatation ≥ 4 cm 570 (37.7%)
 Cervical dilatation ≥ 4 cm among women with PTL 384/728 (52.7%)
 Missing/unknown 227 (15.0%)
N treatment courses/woman 1 [1,1]
 Received more than one course 110 (7.3%)
 Received only loading dose 222 (14.7%)
 Received only maintenance dose 44 (2.9%)
 Received both loading and maintenance doses 1246 (82.4%)
Loading dose details
Route of administration
 IV only 1464 (96.8%)
 IM only 2 (0.1%)
Initial dose (g) 4 [4,4]
Duration of therapy (min) 25 [20, 30]
 Missing 95 (6.5%)
Adverse maternal effects (one/more) 6 (0.4%)
 Maternal hypotension 5 (0.3%)
 Respiratory depression 0
 Pulmonary oedema 1 (0.1%)
Loading dose stopped early 45 (3.1%)
 Stopped because woman delivered 38 (2.6%)
 Stopped because patient refused treatment or further treatment 1 (0.1%)
 Stopped because of maternal side effects 0
 Stopped because woman was no longer in imminent preterm birth 1 (0.1%)
 Other* 4 (0.3%)
Calcium gluconate administered 0
Maintenance dose details
Route of administration
 IV only 1290 (85.3%)
 IM only 0
Initial dose (g/h) 1 [1,1]
Duration of therapy (h) 7.4 [3.1, 17.5]
Adverse maternal effects (one/more) 13 (0.9%)
 Maternal hypotension 3 (0.2%)
 Respiratory depression 0
 Pulmonary oedema 10 (0.7%)
Reasons for stopping maintenance dose
 Stopped because woman delivered 738 (57.2%)
 Stopped because 24 h of therapy had been administered 81 (6.3%)
 Stopped because woman was no longer in imminent preterm birth 163 (12.6%)
 Stopped because of maternal side effects 0
 Other† 29 (2.2%)
 No reason indicated or missing 279 (21.6%)
Calcium gluconate administered 1 (0.1%)
  1. CPN Canadian Perinatal Network
  2. *Other reasons for stopping the loading dose of MgSO4 for fetal NP early were emergency caesarean (N = 1), patient in extreme pain from IV (N = 1), patient felt burning/flushing (N = 1) and unknown (N = 1)
  3. †Other reasons for stopping the maintenance dose of MgSO4 for fetal NP were as per protocol or other orders (e.g. 12 h of therapy administered) (N = 9), dosage change (N = 7), patient transferred (N = 4), MgSO4 continued postpartum for pre-eclampsia prevention (N = 3), fetal demise (N = 2), emergency caesarean (N= 2) or patient experienced side effects (N = 2)